Middle Molecule IT-based Drug Discovery Laboratory (MIDL)
(started operation in March, 2018)
R&D institute that supports middle-molecule (peptides and/or nucleic acids) drug discovery with Tokyo Tech's original technologies including computational techniques and chemical synthesis.
Tenant in RGB2